cmeonhiv.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Editorial board
The Editorial Board of CME on HIV International is an independent committee whose mission is to ensure the scientific quality of the presentations in the online conferences section. Our task is to review and approve these presentations based on the validity of the information they provide. The mission of the CMEonHIV.com Editorial Board also includes attending major conferences on HIV/AIDS so that the most important can be recommended. Last, the Editorial Board firmly believes that the success of CMEonHIV.com depends on the participation of members and on your ideas. Happy surfing!
Dr. Mark A. Wainberg is an internationally recognized scientist in the field of HIV/AIDS, who has made important independent contributions both to the study of virus host interactions and, more importantly, to anti-viral drug development. Professor Wainberg was the first scientist in Canada, beginning in 1984, to work directly on HIV and to isolate the virus from patient populations. His research has helped to define conditions that govern differential infection by HIV of lymphocytic versus monocytic cell populations, and he has also characterized sub-populations of T helper lymphocytes, notably CD4 and CD8 cells, in HIV infection. His work has also dealt with the nature of anti-viral immune responsiveness in individuals infected by HIV. Dr. Wainberg's laboratory was among the first to characterize the phenomenon of HIV escape, through mutagenesis, from immunological pressure.
Dr. Wainberg is recognized internationally for his research in the area of HIV drug development and drug resistance.
He is well known for his initial identification of 3TC as an anti-viral drug, in collaboration with BioChem Pharma Inc. in 1989, and has contributed numerous papers to the international literature on drug action and drug resistance in AIDS. 3TC is today recognized as the most widely used drug in the world in the treatment of HIV disease, and, over time, may be recognized as Canada's most important drug contribution since the discovery of insulin approximately 75 year ago.
Following Dr. Wainberg's research in this area, other Canadian investigators contributed to the discovery that 3TC can also block the replication of hepatitus B virus. Thus, this Canadian developed drug may prove to be effective against two distinct viral diseases. His laboratory continues to work in the area of new drug discovery and, as well, Dr. Wainberg has now turned his attention to novel concepts in HIV vaccine development and prevention of HIV infection. Together with Biochem Pharma, research in Dr. Wainberg's lab has also identified a second anti-HIV compound, dOTC, that is now in clinical trials and that shows great promise.
The role that he has played in HIV/AIDS has been recognized by his election as President of the International AIDS Society for the period 1998-2000. Dr. Wainberg is using his Presidency to advocate for measures that will enhance prevention of HIV infection in developing countries. He was Co-Chair of the Second International Conference on Prevention of Mother-to-Child Transmission of HIV, that took place in Montreal in September, 1999 and will be Co-Chair of an International Conference on HIV Microbicides, planned for Washington in March 2000. He has also led a successful application to bring the International Conference on AIDS, the largest medical conference in the world, back to Canada. Dr. Wainberg will be the Chair of the XV International AIDS Conference, that will take place in Toronto during the summer of 2004.
In a survey of publications on the basic science aspects of HIV/AIDS in highly ranked journals for 1995-97, carried out for the XII International Conference on AID, Dr. Wainberg was ranked 12th in the world and was the only Canadian on a list of the top 50 cited authors. In addition, Dr. Wainberg has been a member of numerous scientific and review committees in Canada, the U.S. and abroad and is a frequent speaker at scientific meetings throughout the world.
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
